News Releases Home Synthetic Biology The History of Synthetic Biology Living Medicines Designing Synthetic Biotic™ Medicines Pipeline + Programs For Patients Our People Leadership Board of Directors Founders and Advisors Join Us Investors + Media Company Overview News & Events News Releases Event Calendar Presentations & Publications Stock Information Corporate Governance Financials Investor Resources Items Per Page 102550 Year None201920182017201620152014 September 4, 2019 Synlogic Announces Appointments of New CMO, Head of Regulatory Affairs, and CFO Departure September 4, 2019 Synlogic Presents Data from Phase 1/2a Study of SYNB1618 at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) August 20, 2019 Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia August 8, 2019 Synlogic to Present at the 2019 Wedbush PacGrow Healthcare Conference August 8, 2019 Synlogic Reports Second Quarter 2019 Financial Results and Provides Program Updates August 1, 2019 Synlogic Announces Second Quarter 2019 Conference Call and Webcast July 15, 2019 Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of Development June 12, 2019 Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic™ Medicines May 22, 2019 Synlogic Announces Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors May 9, 2019 Synlogic Reports First Quarter 2019 Financial Results and Provides Business Update Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 91 Email Alerts Contact IR RSS Feeds Print Page Email Page
Items Per Page 102550 Year None201920182017201620152014 September 4, 2019 Synlogic Announces Appointments of New CMO, Head of Regulatory Affairs, and CFO Departure September 4, 2019 Synlogic Presents Data from Phase 1/2a Study of SYNB1618 at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) August 20, 2019 Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia August 8, 2019 Synlogic to Present at the 2019 Wedbush PacGrow Healthcare Conference August 8, 2019 Synlogic Reports Second Quarter 2019 Financial Results and Provides Program Updates August 1, 2019 Synlogic Announces Second Quarter 2019 Conference Call and Webcast July 15, 2019 Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of Development June 12, 2019 Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic™ Medicines May 22, 2019 Synlogic Announces Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors May 9, 2019 Synlogic Reports First Quarter 2019 Financial Results and Provides Business Update Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 91
September 4, 2019 Synlogic Announces Appointments of New CMO, Head of Regulatory Affairs, and CFO Departure
September 4, 2019 Synlogic Presents Data from Phase 1/2a Study of SYNB1618 at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM)
July 15, 2019 Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of Development
June 12, 2019 Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic™ Medicines
May 22, 2019 Synlogic Announces Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors